Summary:
In adults with newly diagnosed type 2 diabetes mellitus, short-term intensive insulin therapy (SIIT) combined with metformin and pioglitazone or sitagliptin significantly improved glycemic control, reduced insulin requirements, and enhanced β-cell function during treatment compared to SIIT alone via continuous subcutaneous insulin infusion (CSII), though it was associated with no significant difference in 12-month diabetes remission rates.
| PICO | Description |
|---|---|
| Population | Adults with newly diagnosed type 2 diabetes mellitus and a mean HbA1c of 10.6% ± 2.2%. |
| Intervention | Short-term intensive insulin therapy (SIIT) using CSII plus either 90-day oral metformin and pioglitazone (CSII + Met + Pio) or sitagliptin (CSII + Sita). |
| Comparison | SIIT alone for 2 weeks using CSII without additional oral hypoglycemic therapy. |
| Outcome | Both combination groups required lower total insulin doses, had higher time in tight target range and greater acute insulin response after SIIT. At 3 months, more participants in the CSII + Met + Pio group (78.7%) achieved HbA1c < 6.5% than the CSII-only group (59.0%, p < 0.05). However, 12-month remission rates did not significantly differ among groups (p = 0.972). |
Source: Ke, Weijian, et al. “Effects of Short-Term Intensive Insulin Therapy Combined With Oral Hypoglycemic Agents for Inducing Remission in Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Clinical Trial.” Read article here.
